Vertex still neutral, Merrill Lynch says

Vertex Pharmaceuticals Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a neutral rating after the company's VX-950 took the spotlight at an annual medical conference. The neutral rating is maintained mainly due to the rapid run-up of the stock based on early but impressive phase 1 data. As study results for VX-950 combined with PEG-interferon are released, Merrill Lynch said it may review the rating. Shares of the Cambridge, Mass., biotechnology company were down 20 cents, or 0.76%, at $25.99 on volume of 1,646,876 shares versus the three-month running average of 1,518,490 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.